big data |
3 |
singapore |
3 |
advance care planning |
2 |
ageism |
2 |
covid-19 pandemic |
2 |
embryo |
2 |
geriatrics |
2 |
healthcare professionals |
2 |
hong kong |
2 |
public health policy |
2 |
research |
2 |
risk |
2 |
sars outbreak |
2 |
access to medicines |
1 |
affective disorders, psychotic |
1 |
artificial intelligence |
1 |
artificial intelligence (ai) |
1 |
benefit |
1 |
benefit sharing |
1 |
biobanks |
1 |
biomedical research |
1 |
cell proliferation |
1 |
children |
1 |
collective action |
1 |
comparative review |
1 |
conflicts of interest |
1 |
consent |
1 |
corporate social responsibility |
1 |
crime |
1 |
crispr |
1 |
data sharing |
1 |
data system |
1 |
developing economies |
1 |
developmental state |
1 |
dna methylation |
1 |
east asia |
1 |
egg |
1 |
emerging infectious diseases |
1 |
emerging markets |
1 |
environment |
1 |
equity |
1 |
ethics |
1 |
gene-editing |
1 |
genetic discrimination |
1 |
genetic modification |
1 |
genetic screening |
1 |
genetic variability |
1 |
genetics and genomics |
1 |
genomics |
1 |
global action plan |
1 |
governance |
1 |
government regulation |
1 |
health care policy |
1 |
health insurance |
1 |
human |
1 |
human health |
1 |
human-animal combination |
1 |
informed consent |
1 |
institutional review boards |
1 |
international policy |
1 |
key wordsanimal health |
1 |
law |
1 |
law/legal |
1 |
liminality |
1 |
medical devices |
1 |
medical liability |
1 |
medical research ethics |
1 |
nagoya protocol |
1 |
national bioethics committee |
1 |
negligence |
1 |
one health |
1 |
open science |
1 |
participation |
1 |
pathogens sharing |
1 |
personalised medicine |
1 |
pharmaceuticals |
1 |
precision medicine |
1 |
processual |
1 |
professional regulation |
1 |
psychiatry |
1 |
public |
1 |
regulation |
1 |
research ethics |
1 |
research governance |
1 |
research regulation |
1 |
residual tissue |
1 |
stem cell |
1 |
stewardship |
1 |
sustainable biobanking |
1 |
therapeutic misconception |
1 |
trust |
1 |
trustworthiness |
1 |
vulnerable |
1 |
who |
1 |